Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood blood.2024025746.

https://doi.org/10.1182/blood.2024025746

Published: 2024

Includes: Supplemental data

Journal Articles

Using Next Generation Sequencing to Identify Trackable Clonotypic Sequences for Minimal Residual Disease Testing in AL Amyloidosis

Xia Wu, Ping Zhou, Sandy W. Wong, Benjamin Rosenthal, Alfred Chung, Denis Toskic, Stephanie Scalia, Raymond Comenzo

Blood (2023) 142 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2023-190355

Published: 2023

Journal Articles

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2023-174550

Published: 2023

Journal Articles

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2023-182388

Published: 2023

Journal Articles

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Kevin R. Reyes, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5105–5107.

https://doi.org/10.1182/blood-2022-160362

Published: 2022

Journal Articles

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Alfred Chung, Chiung-Yu Huang, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah

Blood (2022) 140 (Supplement 1): 12651–12652.

https://doi.org/10.1182/blood-2022-170744

Published: 2022

Journal Articles

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Aneeqa A Zafar, Chiung-Yu Huang, Mimi Lo, Jen Knoche, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5218–5220.

https://doi.org/10.1182/blood-2022-162122

Published: 2022

Journal Articles

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Sireesha Asoori, Alfred Chung, Nina Shah, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 7233–7234.

https://doi.org/10.1182/blood-2022-168451

Published: 2022

Journal Articles

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Kelsey H. Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 7910–7912.

https://doi.org/10.1182/blood-2022-155906

Published: 2022

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Natasha S Bahri, Alfred Chung, Chiung-Yu Huang, Shagun Arora, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Moming Li, Sandy W. Wong

Blood (2022) 140 (Supplement 1): 4285–4286.

https://doi.org/10.1182/blood-2022-167281

Published: 2022

Journal Articles

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin, Nina Shah, Sandy W. Wong, Jeffrey L. Wolf, Shagun Arora, Alfred Chung

Blood (2022) 140 (Supplement 1): 617–619.

https://doi.org/10.1182/blood-2022-160401

Published: 2022

Journal Articles

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Rahul Banerjee, Ann A. Lazar, Chloe Ryan, Jen Knoche, Kelly Jean Brassil, Lindsey Jackson, Dhiren Patel, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Anand Dhruva, Nina Shah

Blood (2021) 138 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2021-147125

Published: 2021

Journal Articles

Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma

Eva Duvalyan, Mimi Lo, Thomas Martin, Jeffrey L. Wolf, Alfred Chung, Shagun Arora, Nina Shah, Chiung-Yu Huang, Sandy W. Wong

Blood (2021) 138 (Supplement 1): 1759.

https://doi.org/10.1182/blood-2021-146678

Published: 2021

Journal Articles

Cutaneous plasmablastic plasmacytoma

Alfred Chung, Michaela Liedtke

Blood (2019) 134 (23): 2116.

https://doi.org/10.1182/blood.2019002821

Published: 2019

Journal Articles

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, David Iberri, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Richard Lafayette, MD, Sally Arai, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1884.

https://doi.org/10.1182/blood-2019-124981

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

NARROW

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Using Next Generation Sequencing to Identify Trackable Clonotypic Sequences for Minimal Residual Disease Testing in AL Amyloidosis

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing after or Refractory to Anti-BCMA CAR-T Therapies

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Impact of Corticosteroids on Efficacy of BCMA Targeted CAR-T Therapy in Multiple Myeloma

Cutaneous plasmablastic plasmacytoma

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only